SynthesisFrontiers in immunology2026
Immunomodulation for stroke-associated pneumonia: a systematic review of mechanistic insight and emerging therapeutic strategies in animal models.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds and aims: Stroke-associated pneumonia (SAP) is a major infectious complication that increases mortality after stroke. Stroke-induced immunosuppression has been proposed as a key driver of SAP, supporting the rationale for immunomodulation. This review systematically outlines the immunopathology of SAP and evaluates immune-targeted strategies. Methods: Following PRISMA guidelines, we systematically searched PubMed, Scopus, Web of Science, and Embase for studies on the immune mechanisms and immunomodulatory therapies for SAP. Results: We included 38 studies. Evidence from preclinical models indicates that stroke severity disrupts immune homeostasis, driving SAP through a multi-layered network. Systemic immunosuppression is primarily mediated by sympathetic nervous system (SNS) overactivation, inducing splenic atrophy, lymphocyte apoptosis, and impaired innate immune cells (e.g., iNKT cells), whereas the hypothalamic-pituitary-adrenal (HPA) axis appears to contribute less critically. Furthermore, sustained activation of the cholinergic anti-inflammatory pathway (CAP) may impair pulmonary antimicrobial defense. Active intercellular suppression, as exemplified by monocyte-mediated T cell death, has been identified as a potential mechanism that further compromises immunity. Emerging evidence also implicates disruption of the gut-lung axis (e.g., intestinal barrier dysfunction and microbial dysbiosis), local pulmonary alterations, and dysregulation of key immune molecules (e.g., α-MSH, CD147) as potential contributors to SAP development. Interventions targeting these mechanisms (e.g., iNKT cell activator) have shown promise in preclinical models. Conclusion: This review systematically synthesizes the mechanistic basis of SAP and identifies emerging immunomodulatory interventions. While preclinical evidence is encouraging, most strategies remain experimental, and their clinical translation requires considerable further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.